

What is IDEXX Cancer Dx™

…and when/how should I use it in practice?

Dr Clémence Peyron, DVM, DESV

Specialist in Internal Medicine (FR)


Clinician

Medical Affairs and Advocacy Specialist EU

IDEXX laboratories

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Cancer Dx



+ Multi-omics approach
+ Immunoassays + molecular tests
+ New circulating biomarkers, specific to canine lymphoma

© 2026 IDEXX Laboratories, Inc. All rights reserved.


Cancer Dx

- Blood test
- Dog
- 1 ml EDTA blood + 2 ml serum
- Ref Lab
- First-line testing
- TAT 2-5 days


© 2026 IDEXX Laboratories, Inc. All rights reserved.

Cancer Dx

- Blood test
- Dog
- 1 ml EDTA blood + 2 ml serum
- Ref Lab
- First-line testing
- TAT 2-5 days



Lymphoma Specificity




Lymphoma Sensitivity


© 2026 IDEXX Laboratories, Inc. All rights reserved.

Cancer Dx

- Blood test
- Dog
- 1 ml EDTA blood + 2 ml serum
- Ref Lab
- First-line testing
- TAT 2-5 days



Lymphoma Specificity



Lymphoma Sensitivity

If test positive, phenotype included in 56% of cases, at no additional cost to the customer

© 2026 IDEXX Laboratories, Inc. All rights reserved.


Why does phenotype matters?

- Prognosis
- Treatment
- B is Better
- T is Terrible
- But not always!
  - Indolent T cell lymphoma
  - Very aggressive B cell lymphoma
  - DLBCL

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Why does phenotype matters?


- Prognosis
- Treatment
- B is Better
- T is Terrible
- But not always!
  - Indolent T cell lymphoma
  - Very aggressive B cell lymphoma
  - DLBCL



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Why does phenotype matters?

- Prognosis
- Treatment
- B is Better
- T is Terrible
- But not always!
  - Indolent T cell lymphoma
  - Very aggressive B cell lymphoma
  - DLBCL



56% IDEXX Cancer Dx™ results include a phenotype which is highly accurate at no additional cost to customer

© 2026 IDEXX Laboratories, Inc. All rights reserved.

IDEXX Cancer Dx™ for Lymphoma can be used on both well and sick patients



Screened based on population risk factors (no clinical signs)

+ Part of routine preventive care screening
+ Dogs >7
+ At-risk dogs >4

*At-risk dogs include all dogs ≥ 7 years old and high-risk breeds ≥ 4 years old.

Reference

1. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: Data based on testing performed at IDEXX Reference Laboratories in North America between November 1, 2024, and December 6, 2024. *Analysis Report: IDEXX Cancer Dx Validation, 100282* [008_CancerDx-Validation-Report-2.Rmd].

© 2026 IDEXX Laboratories, Inc. All rights reserved.

IDEXX Cancer Dx™ for Lymphoma can be used on both well and sick patients



Screened based on population risk factors (no clinical signs)

+ Part of routine preventive care screening
+ Dogs >7
+ At-risk dogs >4



Clinical signs suggestive of lymphoma

+ Part of diagnostic work-up
+ Accurate, efficient, affordable
+ Increases access to cancer testing and care

*At-risk dogs include all dogs ≥ 7 years old and high-risk breeds ≥ 4 years old.

Reference

1. Data on file at IDEXX Laboratories, Inc. Westbrook, Maine USA: Data based on testing performed at IDEXX Reference Laboratories in North America between November 1, 2024, and December 6, 2024. *Analysis Report: IDEXX Cancer Dx Validation, 100282* [008_CancerDx-Validation-Report-2.Rmd].

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs

Not Consistent with Lymphoma

High concern for lymphoma?

No

Continue diagnostic workup for other causes of clinical signs

Yes

Negative result makes lymphoma less likely but does not rule it out
If suspicion persists, consider lymph node cytology, biopsy with histology, and diagnostic imaging (chest radiographs, abdominal ultrasound)



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs

Not Consistent with Lymphoma

High concern for lymphoma?

No

Continue diagnostic workup for other causes of clinical signs

Yes

Negative result makes lymphoma less likely but does not rule it out
If suspicion persists, consider lymph node cytology, biopsy with histology, and diagnostic imaging (chest radiographs, abdominal ultrasound)

Consistent with Lymphoma

Supports a clinical diagnosis of lymphoma

+ Consider further diagnostics including cytology or biopsy of tissue potentially containing abnormal lymphocytes (lymph nodes, organs, masses) and staging (imaging such as chest radiographs and abdominal ultrasound) to guide treatment/monitoring

+ Consultation with a veterinary oncologist could be considered to determine next steps before referral



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **well** dogs



*American Animal Hospital Association (AAHA) recommends wellness examinations every 6 months in senior dogs and yearly in all other dogs.1

Reference 1. Creevy KE, Grady J, Little SE, et al. 2019 AAHA Canine Life Stage Guidelines. J Am Anim Hosp Assoc. 2019;55(6):267–290. doi:10.5326/JAAHA-MS-6999

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **well** dogs

Not Consistent with Lymphoma

Result supports absence of detectable lymphoma;
evaluate patient at next planned wellness examination*



*American Animal Hospital Association (AAHA) recommends wellness examinations every 6 months in senior dogs and yearly in all other dogs.1

Reference 1. Creevy KE, Grady J, Little SE, et al. 2019 AAHA Canine Life Stage Guidelines. J Am Anim Hosp Assoc. 2019;55(6):267–290. doi:10.5326/JAAHA-MS-6999

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **well** dogs

Not Consistent with Lymphoma

Result supports absence of detectable lymphoma; evaluate patient at next planned wellness examination*



Consistent with Lymphoma

Evaluate full history, physical examination, and blood work

Further evaluation may be considered to confirm presence of disease, including the following:

+ Aspirates or biopsy of lymph nodes/organs
+ Diagnostic imaging (chest radiographs and abdominal ultrasound)
+ Flow cytometry of blood in cases of lymphocytosis

If lymphoma is not detected, perform recheck physical examination in 8-12 weeks (sooner if new symptoms arise)

*American Animal Hospital Association (AAHA) recommends wellness examinations every 6 months in senior dogs and yearly in all other dogs.1

Reference 1. Creevy KE, Grady J, Little SE, et al. 2019 AAHA Canine Life Stage Guidelines. J Am Anim Hosp Assoc. 2019;55(6):267–290. doi:10.5326/JAAHA-MS-6999

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Summary

+ Apparently healthy dog, screening (≥7 years, at-risk breed ≥4 years)

→**Consistent with lymphoma**: lymphoma possible, further examination/monitoring indicated

→**Not consistent with lymphoma**: lymphoma ruled out with confidence at this time



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Summary

+ Apparently healthy dog, screening (≥7 years, at-risk breed ≥4 years)

→**Consistent with lymphoma**: biomarkers detected, further examination/monitoring indicated

→**Not consistent with lymphoma**: lymphoma ruled out with confidence at this time



Sick dog, suspected lymphoma, aid-in-diagnosis

→ **Consistent with lymphoma**: lymphoma very likely, can go for staging, treatment plan, referral

→ **Not consistent with lymphoma**: no biomarker detected, if highly suspicious for lymphoma, further investigations warranted



© 2026 IDEXX Laboratories, Inc. All rights reserved.


Real cases, real decisions



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Confirming Lymphoma


Take actions earlier



Oggy


Background

+ Old male miniature Schnauzer
+ Doing well but enlarged LN




© 2026 IDEXX Laboratories, Inc. All rights reserved.

Take actions earlier



Oggy


Background



+ Old male miniature Schnauzer
+ Doing well but enlarged LN
+ FNA + Cancer Dx → IDEXX
+ FNA: inconclusive although cellularity OK - indolent form or early aggressive form


© 2026 IDEXX Laboratories, Inc. All rights reserved.

Take actions earlier



Oggy

Background




+ Old male miniature Schnauzer
+ Doing well but enlarged LN
+ FNA + Cancer Dx → IDEXX
+ FNA: inconclusive although cellularity OK - indolent form or early aggressive form

→*Send another cytology?*
→*Wait, schedule a follow-up visit and send another sample later?*
→*Go for diagnostic imaging?*


© 2026 IDEXX Laboratories, Inc. All rights reserved.

Take actions earlier



Oggy

Background



+ Old male miniature Schnauzer
+ Doing well but enlarged LN
+ FNA + Cancer Dx → IDEXX
+ FNA: inconclusive although cellularity OK - indolent form or early aggressive form
+ Cancer Dx: consistent with lymphoma, T phenotype

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs

Not Consistent with Lymphoma

High concern for lymphoma?

No

Continue diagnostic workup for other causes of clinical signs

Yes

Negative result makes lymphoma less likely but does not rule it out
If suspicion persists, consider lymph node cytology, biopsy with histology, and diagnostic imaging (chest radiographs, abdominal ultrasound)

Consistent with Lymphoma

Supports a clinical diagnosis of lymphoma

+ Consider further diagnostics including cytology or biopsy of tissue potentially containing abnormal lymphocytes (lymph nodes, organs, masses) and staging (imaging such as chest radiographs and abdominal ultrasound) to guide treatment/monitoring

+ Consultation with a veterinary oncologist could be considered to determine next steps before referral



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs

Not Consistent with Lymphoma

High concern for lymphoma?

No

Continue diagnostic workup for other causes of clinical signs

Yes

Negative result makes lymphoma less likely but does not rule it out. If suspicion persists, consider lymph node cytology, biopsy with histology, and diagnostic imaging (chest radiographs, abdominal ultrasound)

Consistent with Lymphoma

Supports a clinical diagnosis of lymphoma


+ Consider further diagnostics including cytology or biopsy of tissue potentially containing abnormal lymphocytes (lymph nodes, organs, masses) and staging (imaging such as chest radiographs and abdominal ultrasound) to guide treatment/monitoring

+ Consultation with a veterinary oncologist could be considered to determine next steps before referral




© 2026 IDEXX Laboratories, Inc. All rights reserved.

Take actions earlier



Oggy


Background



+ Old male miniature Schnauzer
+ Doing well but enlarged LN
+ FNA + Cancer Dx → IDEXX
+ FNA: inconclusive although cellularity OK - indolent form or early aggressive form
+ Cancer Dx: consistent with lymphoma, T phenotype
+ LN excised → histology → high grade T cell lymphoma


© 2026 IDEXX Laboratories, Inc. All rights reserved.

Take actions earlier



Oggy

Background



+ Old male miniature Schnauzer
+ Doing well but enlarged LN
+ FNA + Cancer Dx → IDEXX
+ FNA: inconclusive although cellularity OK - indolent form or early aggressive form
+ Cancer Dx: consistent with lymphoma, T phenotype
+ LN excised → histology → high grade T cell lymphoma

→ *“Cancer Dx allowed earlier detection, LN removal and earlier diagnosis instead of monitoring and repeating FNA”* *(email from the vet)*

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Finding lymphoma earlier

Ruger



Ruger

- 10-year-old, neutered male Australian shepherd
- Presented in July for wellness visit with senior panel with IDEXX Cancer Dx™ testing at IDEXX Reference Laboratories
- **IDEXX Cancer Dx:** consistent with lymphoma
- **Phenotype:** indeterminate

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Ruger

- 10-year-old, neutered male Australian shepherd
- Presented in July for wellness visit with senior panel with IDEXX Cancer Dx™ testing at IDEXX Reference Laboratories
- **IDEXX Cancer Dx:** consistent with lymphoma
- **Phenotype:** indeterminate

Cancer Dx Lymphoma	a	**Consistent with lymphoma**
Phenotype:	b	Phenotype indeterminate

a A positive result indicates the presence of lymphoma-associated biomarkers and should be interpreted alongside clinical findings. In dogs showing signs of lymphoma, this result supports a clinical diagnosis of lymphoma. Additional diagnostics may be indicated to further characterize and stage the disease. Consultation with a veterinary oncologist to determine appropriate next steps before referral is recommended.
In dogs without clinical signs being screened due to risk profiles, further evaluation may be considered to confirm presence of disease. This may include complete blood count and chemistry panel (if not already pursued), diagnostic imaging , and aspirates of lymph nodes and/or organs. If lymphoma is not identified, monitoring and re-evaluation of peripheral lymph nodes in 8-12 weeks is advised (sooner if new symptoms arise).
Test results do not differentiate clinical aggressiveness. Indolent lymphomas and chronic lymphoid leukemia cases may also be identified. Further testing, including histopathology or flow cytometry, especially if lymphocytosis is present, may help differentiate aggressive from indolent lymphoma.
In rare cases, positive results may reflect other lymphoproliferative cancers such as myeloma-related conditions due to shared cell origin. Interpretation should be guided by clinical context and additional testing.

b In certain cases, the phenotype cannot be confidently determined due to limitations in sample quality, quantity, or marker expression. To further characterize the lymphoid population, consider additional diagnostic modalities such as Lymphoma PCR (PARR) for clonality assessment, flow cytometry for immunophenotyping, or biopsy with immunohistochemistry on tissue containing abnormal lymphocytes.

© 2026 IDEXX Laboratories, Inc. All rights reserved.


Ruger

+ Owners pursued imaging workup and cytology
+ FNA submandibular LN

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Ruger


+ Owners pursued imaging workup and cytology
+ FNA submandibular LN



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Ruger


+ Owners pursued imaging workup and cytology
+ FNA submandibular LN



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Ruger


- Owners pursued imaging workup and cytology
- FNA submandibular LN
- Thoracic radiographs
  - Within normal limits



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Ruger


- Owners pursued imaging workup and cytology
- FNA submandibular LN
- Thoracic radiographs
  - Within normal limits
- Abdominal ultrasound
  - Mesenteric lymphadenopathy



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Ruger

- Owners pursued imaging workup and cytology
- FNA submandibular LN
- Thoracic radiographs
  - Within normal limits
- Abdominal ultrasound
  - Mesenteric lymphadenopathy
- PARR testing
  - Immunoglobulin gene: clonal
  - T-cell receptor: polyclonal
  - Consistent with B-cell



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Ruger



01

Stage III: Multicentric lymphoma with confirmed on both sides of diaphragm.

02

Substage a: Patient is clinically well without systemic illness at time of diagnosis.

03

Referred to oncology for options.

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Ruling out lymphoma in a symptomatic dog

Betowen, x Bernese Mountain dog, 4 years old

- Intermittent hyperthermia
- Waxing and waning mental dullness
- CRP >100
- CBC, BC, electrolytes, UA within normal limits



© 2026 IDEXX Laboratories, Inc. All rights reserved.


Betowen, x Bernese Mountain dog, 4 years old





+ Intermittent hyperthermia
+ Waxing and waning mental dullness
+ CRP >100
+ CBC, BC, electrolytes, UA within normal limits

→ Diagnostic imaging


© 2026 IDEXX Laboratories, Inc. All rights reserved.


R



R















Precision+







Betowen, x Bernese Mountain dog, 4 years old



+ Intermittent hyperthermia
+ Waxing and waning mental dullness
+ CRP >100
+ CBC, BC, electrolytes, UA within normal limits

→Diagnostic imaging

→Neoplastic process VERY likely

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Betowen, x Bernese Mountain dog, 4 years old



+ Intermittent hyperthermia
+ Waxing and waning mental dullness
+ CRP >100
+ CBC, BC, electrolytes, UA within normal limits

→Diagnostic imaging

→Neoplastic process VERY likely

→More likely HSA (CRP, mental dullness, imaging, breed…)

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Betowen, x Bernese Mountain dog, 4 years old



+ Intermittent hyperthermia
+ Waxing and waning mental dullness
+ CRP >100
+ CBC, BC, electrolytes, UA within normal limits

→Diagnostic imaging

→Neoplastic process VERY likely

→More likely HSA (CRP, mental dullness, imaging, breed…)

→BUT could also be a lymphoma (or something else)

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Betowen, x Bernese Mountain dog, 4 years old



+ Intermittent hyperthermia
+ Waxing and waning mental dullness
+ CRP >100
+ CBC, BC, electrolytes, UA within normal limits

→Diagnostic imaging

→Neoplastic process VERY likely

→More likely HSA (CRP, mental dullness, imaging, breed…)

→BUT could also be a lymphoma (or something else)

+ Budget not unlimited
+ Cytology uncertain

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Betowen, x Bernese Mountain dog, 4 years old



+ Intermittent hyperthermia
+ Waxing and waning mental dullness
+ CRP >100
+ CBC, BC, electrolytes, UA within normal limits

→Diagnostic imaging


→Neoplastic process VERY likely

→More likely HSA (CRP, mental dullness, imaging, breed…)

→BUT could also be a lymphoma (or something else)

+ Budget not unlimited
+ Cytology uncertain

→Cancer Dx



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Betowen, x Bernese Mountain dog, 4 years old



+ Intermittent hyperthermia
+ Waxing and waning mental dullness
+ CRP >100
+ CBC, BC, electrolytes, UA within normal limits

→Diagnostic imaging

→Neoplastic process VERY likely

→More likely HSA (CRP, mental dullness, imaging, breed…)

→BUT could also be a lymphoma (or something else)

+ Budget not unlimited
+ Cytology uncertain

→Cancer Dx

→Negative



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs

Not Consistent with Lymphoma

High concern for lymphoma?

No

Continue diagnostic workup for other causes of clinical signs

Yes

Negative result makes lymphoma less likely but does not rule it out
If suspicion persists, consider lymph node cytology, biopsy with histology, and diagnostic imaging (chest radiographs, abdominal ultrasound)

Consistent with Lymphoma

Supports a clinical diagnosis of lymphoma

+ Consider further diagnostics including cytology or biopsy of tissue potentially containing abnormal lymphocytes (lymph nodes, organs, masses) and staging (imaging such as chest radiographs and abdominal ultrasound) to guide treatment/monitoring

+ Consultation with a veterinary oncologist could be considered to determine next steps before referral



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs

Not Consistent with Lymphoma

High concern for lymphoma?

No

Continue diagnostic workup for other causes of clinical signs

Yes

Negative result makes lymphoma less likely but does not rule it out
If suspicion persists, consider lymph node cytology, biopsy with histology, and diagnostic imaging (chest radiographs, abdominal ultrasound)

Consistent with Lymphoma

Supports a clinical diagnosis of lymphoma

+ Consider further diagnostics including cytology or biopsy of tissue potentially containing abnormal lymphocytes (lymph nodes, organs, masses) and staging (imaging such as chest radiographs and abdominal ultrasound) to guide treatment/monitoring

+ Consultation with a veterinary oncologist could be considered to determine next steps before referral



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs

Not Consistent with Lymphoma

High concern for lymphoma?

No

Continue diagnostic workup for other causes of clinical signs

Yes

Negative result makes lymphoma less likely but does not rule it out
If suspicion persists, consider lymph node cytology, biopsy with histology, and diagnostic imaging (chest radiographs, abdominal ultrasound)

Consistent with Lymphoma

Supports a clinical diagnosis of lymphoma


+ Consider further diagnostics including cytology or biopsy of tissue potentially containing abnormal lymphocytes (lymph nodes, organs, masses) and staging (imaging such as chest radiographs and abdominal ultrasound) to guide treatment/monitoring

+ Consultation with a veterinary oncologist could be considered to determine next steps before referral



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Betowen, x Bernese Mountain dog, 4 years old



+ Intermittent hyperthermia
+ Waxing and waning mental dullness
+ CRP >100
+ CBC, BC, normal lim

Would have been interesting to run a Cancer Dx for hemangiosarcoma...

→Diagnostic imaging

→Neoplastic process VERY likely

→More likely HSA (CRP, mental dullness, imaging, breed…)

→BUT could also be a lymphoma (or something else)

+ Budget not unlimited
+ Cytology uncertain

→Cancer Dx

→Negative



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Cancer Dx when FNA not possible

Bobtail, 9 years old

+ Enlarged lymph nodes
+ Severe thrombocytopenia



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Bobtail, 9 years old

+ **Enlarged lymph nodes**
+ Severe thrombocytopenia



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Bobtail, 9 years old

+ **Enlarged lymph nodes**
+ Severe thrombocytopenia
→**Neoplastic process?**
→**Antigenic stimulation?**
→**Infectious disease?**



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Bobtail, 9 years old

+ **Enlarged lymph nodes**
+ Severe thrombocytopenia
→**Neoplastic process?**
→**Antigenic stimulation?**
→**Infectious disease?**



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Bobtail, 9 years old

+ **Enlarged lymph nodes**
+ Severe thrombocytopenia
→**Neoplastic process?**
→**Antigenic stimulation?**
→**Infectious disease?**
→Immune-mediated process?



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Bobtail, 9 years old



+ **Enlarged lymph nodes**
+ Severe thrombocytopenia
→**Neoplastic process?**
→**Antigenic stimulation?**
→**Infectious disease?**
→Immune-mediated process?

Primary or secondary to inflammatory, infectious, neoplastic process

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Bobtail, 9 years old



+ **Enlarged lymph nodes**
+ Severe thrombocytopenia
→**Neoplastic process?**
→**Antigenic stimulation?**
→**Infectious disease?**
→Immune-mediated process?

Primary or secondary to inflammatory, infectious, neoplastic process

→FNA not recommended (thrombocytopenia)
→Cancer Dx

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Bobtail, 9 years old



+ **Enlarged lymph nodes**
+ Severe thrombocytopenia

→**Neoplastic process?**

→**Antigenic stimulation?**


→**Infectious disease?**

→Immune-mediated process?

Primary or secondary to inflammatory, infectious, neoplastic process

→FNA not recommended (thrombocytopenia)

→Cancer Dx



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Bobtail, 9 years old



+ **Enlarged lymph nodes**
+ Severe thrombocytopenia
→**Neoplastic process?**
→**Antigenic stimulation?**
→**Infectious disease?**
→Immune-mediated process?

Primary or secondary to inflammatory, infectious, neoplastic process

→FNA not recommended (thrombocytopenia)
→Cancer Dx
→Positive for T cell lymphoma



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs

Not Consistent with Lymphoma

High concern for lymphoma?

No

Continue diagnostic workup for other causes of clinical signs

Yes

Negative result makes lymphoma less likely but does not rule it out
If suspicion persists, consider lymph node cytology, biopsy with histology, and diagnostic imaging (chest radiographs, abdominal ultrasound)

Consistent with Lymphoma

Supports a clinical diagnosis of lymphoma

+ Consider further diagnostics including cytology or biopsy of tissue potentially containing abnormal lymphocytes (lymph nodes, organs, masses) and staging (imaging such as chest radiographs and abdominal ultrasound) to guide treatment/monitoring

+ Consultation with a veterinary oncologist could be considered to determine next steps before referral



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs

Not Consistent with Lymphoma

High concern for lymphoma?

No

Continue diagnostic workup for other causes of clinical signs

Yes

Negative result makes lymphoma less likely but does not rule it out
If suspicion persists, consider lymph node cytology, biopsy with histology, and diagnostic imaging (chest radiographs, abdominal ultrasound)

Consistent with Lymphoma

Supports a clinical diagnosis of lymphoma

+ Consider further diagnostics including cytology or biopsy of tissue potentially containing abnormal lymphocytes (lymph nodes, organs, masses) and staging (imaging such as chest radiographs and abdominal ultrasound) to guide treatment/monitoring

+ Consultation with a veterinary oncologist could be considered to determine next steps before referral



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Cancer Dx + inVue

Mixbreed, 8 years old



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Mixbreed, 8 years old

+ Weight loss
+ Poor appetite
+ Diarrhea/vomiting



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Mixbreed, 8 years old



Leucocytes	C **23,40**	**5,05 - 18,60 x10^9/L**	H	
% Neutrophiles segmentés	22,5	%		
% neutrophiles immatures	0,0	%		
% Lymphocytes	71,3	%		
% Monocytes	4,1	%		
% Eosinophiles	2,0	%		
% Basophiles	0,1	%		
Neutrophiles	5,26	2,92 - 13,80 x10^9/L		
Neutrophiles immatures	0,00	x10^9/L		
Lymphocytes	**16,69**	**0,76 - 4,40 x10^9/L**	H	
Monocytes	0,95	0,31 - 1,95 x10^9/L		
Éosinophiles	0,47	0,06 - 1,23 x10^9/L		
Basophiles	0,02	0,00 - 0,10 x10^9/L		
Plaquettes				

Mixbreed, 8 years old



Leucocytes	C	**23,40**	
% Neutrophiles segmentés		22,5	
% neutrophiles immatures		0,0	
% Lymphocytes		71,3	
% Monocytes		4,1	
% Eosinophiles		2,0	
% Basophiles		0,1	
Neutrophiles		5,26	
Neutrophiles immatures		0,00	
Lymphocytes		**16,69**	
Monocytes		0,95	
Éosinophiles		0,47	
Basophiles		0,02	0,00 - 0,10 x10^9/L
Plaquettes			



Mixbreed, 8 years old



Leucocytes	C **23,40**	**5,05 - 18,60 x10^9/L**	H
% Neutrophiles segmentés	22,5	%	
% neutrophiles immatures	0,0	%	
% Lymphocytes			
% Monocytes			
% Eosinophiles			
% Basophiles			
Neutrophiles			
Neutrophiles immatures			
Lymphocytes	**16,69**	**0,76 - 4,40 x10^9/L**	H
Monocytes	0,95	0,31 - 1,95 x10^9/L	
Éosinophiles	0,47	0,06 - 1,23 x10^9/L	
Basophiles	0,02	0,00 - 0,10 x10^9/L	
Plaquettes			

La présence d'eccentrocytes indique une atteinte oxydative des érythrocytes, qui peut se produire à la suite d'une exposition à des médicaments/toxines (p. ex., zinc, oignon, ail, boules antimites, paracétamol, vitamine K ou rodenticides) ou, moins souvent, dans certains états pathologiques (p. ex., diabète sucré, lymphome et infections sévères).

Mixbreed, 8 years old



Leucocytes	C **23,40**	**5,05 - 18,60 x10^9/L**	H
% Neutrophiles segmentés	22,5	%	
% neutrophiles immatures	0,0	%	
% Lymphocytes			
% Monocytes			
% Eosinophiles			
% Basophiles			
Neutrophiles			
Neutrophiles immatures			
Lymphocytes	**16,69**	**0,76 - 4,40 x10^9/L**	H
Monocytes	0,95	0,31 - 1,95 x10^9/L	
Éosinophiles	0,47	0,06 - 1,23 x10^9/L	
Basophiles	0,02	0,00 - 0,10 x10^9/L	
Plaquettes			

La présence d'eccentrocytes indique une atteinte oxydative des
érythrocy les
médicamen
paracétan
états pat
sévères).

Eccentrocytes: possible RBC oxidative damage, diabetes mellitus, lymphoma, severe infection

Mixbreed, 8 years old



+ Weight loss
+ Poor appetite
+ Diarrhea/vomiting
+ Marked lymphocytosis
+ Eccentrocytes detected
+ BC: ALT 273 U/L

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Mixbreed, 8 years old



+ Weight loss
+ Poor appetite
+ Diarrhea/vomiting
+ Marked lymphocytosis
+ Eccentrocytes detected
+ BC: ALT 273 U/L

→Lymphoma? Lymphoid leukemia?

→Antigenic stimulation?

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Mixbreed, 8 years old



+ Weight loss
+ Poor appetite
+ Diarrhea/vomiting
+ Marked lymphocytosis
+ Eccentrocytes detected
+ BC: ALT 273 U/L

→Lymphoma? Lymphoid leukemia?

→Antigenic stimulation?

+ Diagnostic imaging

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Mixbreed, 8 years old



+ Weight loss
+ Poor appetite
+ Diarrhea/vomiting
+ Marked lymphocytosis
+ Eccentrocytes detected
+ BC: ALT 273 U/L

→Lymphoma? Lymphoid leukemia?

→Antigenic stimulation?

+ Diagnostic imaging

→ Hepatomegaly, hepatic mass

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Mixbreed, 8 years old



+ Weight loss
+ Poor appetite
+ Diarrhea/vomiting
+ Marked lymphocytosis
+ Eccentrocytes detected
+ BC: ALT 273 U/L

→Lymphoma? Lymphoid leukemia?

→Antigenic stimulation?

+ Diagnostic imaging

→ Hepatomegaly, hepatic mass

+ Hepatic cytology

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Mixbreed, 8 years old



+ Weight loss
+ Poor appetite
+ Diarrhea/vomiting
+ Marked lymphocytosis
+ Eccentrocytes detected
+ BC: ALT 273 U/L

→Lymphoma? Lymphoid leukemia?

→Antigenic stimulation?

+ Diagnostic imaging

→ Hepatomegaly, hepatic mass

+ Hepatic cytology

→ Many lymphocytes

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Mixbreed, 8 years old



+ Weight loss
+ Poor appetite
+ Diarrhea/vomiting
+ Marked lymphocytosis
+ Eccentrocytes detected
+ BC: ALT 273 U/L

→Lymphoma? Lymphoid leukemia?

→Antigenic stimulation?


+ Diagnostic imaging

→ Hepatomegaly, hepatic mass

+ Hepatic cytology

→ Many lymphocytes

+ Cancer Dx



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Mixbreed, 8 years old



+ Weight loss
+ Poor appetite
+ Diarrhea/vomiting
+ Marked lymphocytosis
+ Eccentrocytes detected
+ BC: ALT 273 U/L

→Lymphoma? Lymphoid leukemia?

→Antigenic stimulation?

+ Diagnostic imaging


→ Hepatomegaly, hepatic mass

+ Hepatic cytology

→ Many lymphocytes

+ Cancer Dx

→ Positive



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs

Not Consistent with Lymphoma

High concern for lymphoma?

No

Continue diagnostic workup for other causes of clinical signs

Yes

Negative result makes lymphoma less likely but does not rule it out
If suspicion persists, consider lymph node cytology, biopsy with histology, and diagnostic imaging (chest radiographs, abdominal ultrasound)

Consistent with Lymphoma

Supports a clinical diagnosis of lymphoma

+ Consider further diagnostics including cytology or biopsy of tissue potentially containing abnormal lymphocytes (lymph nodes, organs, masses) and staging (imaging such as chest radiographs and abdominal ultrasound) to guide treatment/monitoring

+ Consultation with a veterinary oncologist could be considered to determine next steps before referral



© 2026 IDEXX Laboratories, Inc. All rights reserved.

Translating results into clinical decisions: Clinically **ill** dogs

Not Consistent with Lymphoma

High concern for lymphoma?

No

Continue diagnostic workup for other causes of clinical signs

Yes

Negative result makes lymphoma less likely but does not rule it out
If suspicion persists, consider lymph node cytology, biopsy with histology, and diagnostic imaging (chest radiographs, abdominal ultrasound)

Consistent with Lymphoma

Supports a clinical diagnosis of lymphoma

+ Consider further diagnostics including cytology or biopsy of tissue potentially containing abnormal lymphocytes (lymph nodes, organs, masses) and staging (imaging such as chest radiographs and abdominal ultrasound) to guide treatment/monitoring

+ Consultation with a veterinary oncologist could be considered to determine next steps before referral



© 2026 IDEXX Laboratories, Inc. All rights reserved.



IDEXX Cancer Dx™:


Lymphoma is just the beginning

IDEXX

Canine multi-cancer panel transforms screening and care

Lymphoma

Available US & EU



Diagnosis when patient is asymptomatic associated with increased survival time(1)

24%

Percentage of Canine Cancer Cases Covered*

(1) Keller, E.T., MacEwen, E.G, et al. (1993)
(2) Ong SM, McKenna C, et al. (2025)
(3) Wendelburg KM, Price LL, et al. (2015)


* Estimates based on analysis of publicly available incidence data and peer-reviewed literature
** Absence of metastatic disease

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Canine multi-cancer panel transforms screening and care

Lymphoma

Available US & EU




Diagnosis when patient is asymptomatic associated with increased survival time(1)

24%

Mast Cell Tumor

Available US



Early-stage diagnosis** 7x higher odds surviving 2+ years(2)

35%

Percentage of Canine Cancer Cases Covered*

(1) Keller, E.T., MacEwen, E.G, et al. (1993)
(2) Ong SM, McKenna C, et al. (2025)
(3) Wendelburg KM, Price LL, et al. (2015)


* Estimates based on analysis of publicly available incidence data and peer-reviewed literature
** Absence of metastatic disease

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Canine multi-cancer panel transforms screening and care

Lymphoma

Available US & EU




Diagnosis when patient is asymptomatic associated with increased survival time(1)

24%

Mast Cell Tumor

Available US




Early-stage diagnosis** 7x higher odds surviving 2+ years(2)

35%

Hemangiosarcoma

Coming soon US



Pre-rupture detection doubles a dog's odds of surviving to one year(3)

40%

Percentage of Canine Cancer Cases Covered*

(1) Keller, E.T., MacEwen, E.G, et al. (1993)
(2) Ong SM, McKenna C, et al. (2025)
(3) Wendelburg KM, Price LL, et al. (2015)


* Estimates based on analysis of publicly available incidence data and peer-reviewed literature
** Absence of metastatic disease

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Canine multi-cancer panel transforms screening and care

Lymphoma

Available US & EU




Diagnosis when patient is asymptomatic associated with increased survival time(1)

24%

Mast Cell Tumor

Available US




Early-stage diagnosis** 7x higher odds surviving 2+ years(2)

35%

Hemangiosarcoma

Coming soon US




Pre-rupture detection doubles a dog's odds of surviving to one year(3)

40%

Panel Expansion

Until 2028



IDEXX Cancer Dx will expand to include detection for more than half of canine cancers

50%+

Percentage of Canine Cancer Cases Covered*

Spring 2027 in EU

(1) Keller, E.T., MacEwen, E.G, et al. (1993)
(2) Ong SM, McKenna C, et al. (2025)
(3) Wendelburg KM, Price LL, et al. (2015)

* Estimates based on analysis of publicly available incidence data and peer-reviewed literature
** Absence of metastatic disease

© 2026 IDEXX Laboratories, Inc. All rights reserved.

From “catch everything” to **trust the result**

Then: Chase sensitivity

Screening dogma taught to maximize sensitivity, even if specificity suffers. “Better a false alarm than a missed cancer."

Now: We’ve seen the cost

In low-prevalence populations that trade-off backfires. PSA screening lived it: up to 75% of biopsies were unnecessary. [1,2]

Next: Prioritize specificity

Maximize specificity. PPV climbs sharply, and NPV stays strong even at lower sensitivity: a reassuring no, and a yes worth acting on.

The Cancer Dx Panel is built for this next chapter: specificity that turns a positive into a signal worth acting on, and a negative into real reassurance.



[1] PSA Screening for Prostate Cancer. Am Fam Physician. 2015. [2] Loeb S, et al. Whom to Biopsy: Pre-Diagnostic Risk Stratification. Rev Urol.

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Pet Parents and Veterinarians want early cancer detection

PET PARENTS

CONCERN

61%

are concerned about the **risk of cancer** in their dog

INTEREST

73%

are interested in having a cancer **screening test** for their pet



VETERINARIANS

LIKELIHOOD

89%

Answered “Likely” to **adding a cancer screening to wellness protocols**

IMPACT

86%

Indicated cancer screening would have **a “Positive Impact” on their practice**

© 2026 IDEXX Laboratories, Inc. All rights reserved.
CONFIDENTIAL – INTERNAL USE ONLY

Source: IDEXX Quantitative Research with Dog Owners, May 2024 (n = 480)
Source: IDEXX Quantitative Research with General Practitioners, April 2024 (n = 319)

IDEXX


PSV
The gap is not
“Can we diagnose cancer once it is suspected?”
The true gap is
“Can we diagnose cancer when it is not obvious?”

Advancing cancer screening through multi-cancer detection



1 in 4 Dogs will be diagnosed with cancer in their lifetime

The Goal of Screening

1. Identify patients that benefit from additional investigation



2. Additional diagnostics earlier, leading to earlier confirmation

Earlier detection creates opportunities for **earlier intervention, informed clinical decision-making,** and **improved care**

© 2026 IDEXX Laboratories, Inc. All rights reserved.

Screening is appropriate for the at-risk populations in wellness protocols

Senior Dogs

Age 7+ • all breeds

+ Cancer risk climbs sharply once dogs enter their senior years
+ Represents the largest at-risk population moving through practices every year
+ Screening layers directly into the routine wellness exam



High-Risk Breeds

Age 4+ • predisposed breeds

Golden Retriever	Boxer
Rottweiler	Bernese Mtn. Dog
Labrador Retriever	Beagle
Doberman Pinscher	German Shepherd
And others...	


No added visit, no added friction. Both groups are screened in a visit that's already scheduled, turning routine wellness care into a repeatable cancer-screening opportunity.

© 2026 IDEXX Laboratories, Inc. All rights reserved.

(1) Boyd, C., et al. Age at cancer diagnosis by breed, weight, sex, and cancer type in >3,000 dogs. Front Vet Sci (2023)


Stop waiting for suspicion. Start screening at-risk dogs.

THEN



- Lymphoma-focused
- Often discussed when cancer is suspected
- Single-cancer mindset

NOW



- Multi-screening panel
- At-risk, apparently healthy dogs
- Routine wellness care

No suspicion?

SCREEN.

Positive?

WORK-UP.

Negative?

REASSURE.

See a mass?

POKE THE MASS.

WITH THE PANEL. START WITH WELLNESS. MAKE SCREENING ROUTINE.

Screen what you can’t see. Work-up what you find.


© 2026 IDEXX Laboratories, Inc. All rights reserved.

IDEXX MEDICAL

Merci!

clemence-peyron@idexx.com




IDEXX